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ABSTRACT. In the biosynthesis of steroid hormones the
neutral lipid cholesterol, a normal constituent of lipid bi-
layers is transformed via a series of hydroxylation, oxida-
tion, and reduction steps into a vast array of biologically
active compounds: mineralocorticoids, glucocorticoids, and
sex hormones. Glucocorticoids regulate many aspects of
metabolism and immune function, whereas mineralocorti-
coids help maintain blood volume and control renal excre-
tion of electrolytes. Sex hormones are essential for sex dif-
ferentiation in male and support reproduction. They include
androgens, estrogens, and progestins. A block in the path-
way of steroid biosynthesis leads to the lack of hormones
downstream and accumulation of the upstream compounds
that can activate other members of the steroid receptor
family. This review deals with the clinical consequences of
these blocks.
(J. Endocrinol. Invest. 33: 756-766, 2010)
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Steroid hormones are derivatives of cholesterol that are
synthesized by a variety of tissues, most prominently the
adrenal gland and gonads, although other tissues, such
as liver, kidney, placenta, brain, and skin are also quite
active. The cholesterol precursor can be synthesized with-
in the cell from acetate, or derive from cholesterol ester
stores in intracellular lipid droplets or from uptake of
cholesterol-containing LDL. Lipoproteins taken up from
plasma are most important when steroidogenic cells are
chronically stimulated.
The basic cyclopentanoperhydrophenanthrene ring struc-
ture and carbon numbering system of all steroid hor-
mones is depicted in Figure 1, using pregnenolone as an
example. Pregnenolone is an example of what is called a
“C-21 steroid” because it has 21 carbons. Similarly, a
steroid such as testosterone is referred to as a “C-19
steroid”.
Biosynthesis of steroid hormones requires a battery of
oxidative enzymes located in both mitochondria and en-
doplasmic reticulum. The rate-limiting step in this pro-
cess is the transport of free cholesterol from the cyto-
plasm into mitochondria. Within mitochondria, choles-
terol is converted to pregnenolone by an enzyme in the
inner membrane called cytochrome P450 (see the Ap-
pendix) side-chain cleavage (P450scc). Pregnenolone it-
self is not a hormone but is the immediate precursor for
the synthesis of all of the steroid hormones.
Typically, endocrinologists classify steroid hormones in-
to 5 groups of molecules, based primarily on the recep-
tor to which they bind:
- glucocorticoids; cortisol is the major representative in
humans
- mineralocorticoids; aldosterone being most prominent
- androgens such as testosterone
- estrogens, including estradiol and estrone
- progestogens (also known as progestins) such as pro-
gesterone.
The biosynthetic pathways for major representatives of
these classes of steroid hormones is depicted in Figure 2.
Steroid hormones bind to specific intracellular receptors
which upon dimerization interact with the DNA in the nu-
cleus. As a result, gene activity is modulated and a hor-
mone-specific response occurs.
Defects in the receptor or the post-receptor machinery
will lead for the most part to abnormalities of action of
one specific hormone. Abnormalities of steroid hormone
production, however, can result in more profound and
complex effects. A block in the pathway of steroid biosyn-
thesis leads to the lack of hormones downstream and ac-
cumulation of the upstream compounds that can activate
other members of the steroid receptor family.
The consequences of such defects can be schematically
categorized in 3 groups:
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Fig. 1 - Basic cyclopentanoperhydrophenanthrene ring structure
and carbon numbering system of all steroid hormones, using
pregnenolone as example.
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1. defects leading to disorders of sex development (DSD)
(1) and salt-water balance;
2. defects leading to abnormalities of salt-water balance;
3. defects leading to disorders of sex development.
Defective genes and clinical consequences of their de-
fects are briefly summarized in Table 1.
Abnormalities of end-organ action of steroid hormones,
exemplified by the hormone insensitivity syndromes can
be grouped in a 4th category.
DEFECTS LEADING TO ABNORMALITIES OF SEX
DEVELOPMENT AND SALT-WATER BALANCE
The first group of steroid biosynthesis defects include the
so-called congenital adrenal hyperplasia (CAH), a collec-
tive name given to a group of disorders characterized by
inherited inability of the adrenals to secrete cortisol. The
consequent compensatory rise of ACTH production caus-
es hyperplastic growth of the adrenal glands. Blocks of
the initial steps of the steroidogenic pathway impair the
production of all the 3 types of steroids, causing abnor-
malities in the salt-water homeostasis and in sexual differ-
entiation. That is the case in lipoid adrenal hyperplasia,
where no conversion of cholesterol to any steroid takes
place. This rare cause of CAH is characterized by salt-loss
and and 46, XY DSD. In XX subjects internal and external
genitalia are female, and the syndrome cannot clinically
be separated from congenital adrenal hypoplasia (2). The
molecular bases of such a defect have been clarified as
mutations in the Steroidogenic Acute Response Protein
(StAR) (3). Recently, Kim et al. screened nine 46,XY infants
with adrenal failure and disordered sexual differentiation
for mutations in the CYP11A1 gene encoding cytochrome
P450scc and identified 2 patients, both compound het-
erozygotes, bringing the total number of patients with
CYP11A1 mutations to 6. Among the 6 patients, the phe-
notypic spectrum ranged from severe loss-of-function mu-
tations associated with prematurity, complete underan-
drogenization, and severe, early-onset adrenal failure, to
partial deficiencies found in children born at term with cli-
Fig. 2 - Steroidogenic pathway. A: Metabo-
lites in black, P450 enzyme activities in
grey, other enzyme families in light grey.
B: metabolites in black, genes in grey.
SCC: P450 side-chain-cleavage; StAR:
steroidogenic acute response protein;
POR: P450 oxido reductase; HSD: hydrox-
ysteroid dehydrogenase; H6PDH: hexose-
6-phosphate dehydrogenase; CYP: cy-
tochrome P450.
A Cholesterol
Pregnenolone
Progesterone
Deoxycorticosterone
(DOC)
Corticosterone
(B)
18OH Corticosterone
Aldosterone
17OH-pregnenolone
17OH-Progesterone
11-Deoxycortisol
Cortisol
Cortisone
DHEA
Androstenedione
Testosterone
Dihydrotestosterone
(DHT)
Estradiol
Aromatase5α-Reductase
17β-HSD
3β-HSD
17,20-Lyase
17,20-Lyase
21-Hydroxylase
3β-HSD
11β-HSD2
11β-Hydroxylase
11β-HSD1
H6PDH
POR
SCC/StAR
17α-Hydroxylase
17α-Hydroxylase
21-Hydroxylase
11β-Hydroxylase
Aldo synthase
(Corticosterone Methyl
Oxidase I)
Aldo synthase
(Corticosterone Methyl
Oxidase II)
POR
POR
B Cholesterol
Pregnenolone
Progesterone
Deoxycorticosterone
(DOC)
Corticosterone
(B)
18OH Corticosterone
Aldosterone
Mineralocorticoids
(Salt - Water Homeostasis)
17OH-pregnenolone
17OH-Progesterone
11-Deoxycortisol
Cortisol
Cortisone
Glucocorticoids
(Stress response)
DHEA
Androstenedione
Testosterone
Sex hormones
Dihydrotestosterone
(DHT)
Estradiol
CYP19SRD5A2
HSD17B3
HSD3B2
CYP17A1
CYP17A1
CYP21A2
HSD3B2
HSD11B2
CYP11B1
HSD11B1
H6PD
POR
CYP11A1/StAR
CYP17A1
CYP17A1
CYP21A2
CYP11B1
CYP11B2
CYP11B2
POR
POR
HSD3B2
Defects of steroidogenesis
758
toromegaly and later-onset adrenal failure. The authors of
this work noted that, in contradistinction to congenital
lipoid adrenal hyperplasia caused by StAR mutations,
adrenal hyperplasia had not been reported in any of the 6
patients with P450scc deficiency (4).
P450c17 (17a-hydroxylase/17,20-lyase)
The enzyme P450c17 plays an important role in steroid
production. It is essential for the synthesis of cortisol as
well as the production of sex steroids. P450c17 has two
distinct activities: 17α-hydroxylase activity and 17,20-
lyase activity.
The ratio of the 17α-hydroxylase to 17,20 lyase activities of
human P450c17 is developmentally regulated. Adjusted
for body size, the human adrenal produces nearly constant
amounts of cortisol throughout life, indicating relatively
constant hydroxylase activity (5). By contrast, the produc-
tion of DHEA is minimal in childhood, rises 100-fold to lev-
els that exceed the production of cortisol in young adult-
hood, and then gradually decreases with advancing age
(6). The mechanisms by which human adrenal C19 steroid
synthesis is turned on (adrenarche) and turned off
(adrenopause) remain unclear. Recent clinical observations
suggest a link between premature exaggerated adrenar-
che and the polycystic ovary syndrome (7-10).
P450c17 is a single enzyme encoded by a single gene
that is expressed in both the adrenals and gonads (11-
13). Like other microsomal P450 enzymes, P450c17 cat-
alyzes several chemical reactions on a single active site
by receiving electrons from the flavoprotein P450 oxi-
doreductase. Human P450c17 can catalyze the 17-αhy-
droxylation of pregnenolone to OH-pregnenolone
(17OH-Preg) or of progesterone to OH progesterone
(17OH-Prog). However, the 17,20 lyase reaction almost
Gene Chromosome Molecular defect Sexual development Other organs
XY XX Both sexes
LOF: Loss-of-Function. See text for abbreviations.
Table 1 - Steroidogenesis: effect of mutation.
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exclusively converts 17OH-Preg to DHEA; human
P450c17 catalyzes the conversion of 17OH-Prog to an-
drostenedione with only 3% of the efficiency of the re-
action with 17OH-Preg (13); thus, most human sex
steroids are made from DHEA. At least 3 factors influ-
ence the ratio of 17,20 lyase to 17α-hydroxylase activi-
ties at a post-translational level. First, high molar ratios
of P450 oxidoreductase to P450c17 favor lyase activity
(14). Second, cytochrome b5, an ubiquitous electron
transport hemoprotein, acts allosterically to foster the
interaction between P450c17 and P450 oxidoreductase
to promote the lyase reaction, but b5 does not function
as an electron donor (13-15). Third, the phosphorylation
of P450c17 on serine and threonine but not tyrosine
residues increases 17,20 lyase activity through as-yet-
unidentified mechanisms, which may involve increasing
its affinity for b5 and/or P450 oxidoreductase (16). Mu-
tations throughout the gene have been described as
leading to P450c17 deficiency. Rare cases of isolated
17,20-lyase deficiency have been reported. However, in
most cases of P450c17 deficiency, both activities are re-
duced. Such combined 17α-hydroxylase/17,20-lyase-de-
ficiency usually leads to a severe defect in the production
of cortisol and sex steroids. In affected males this results
in impaired masculinization with ambiguous or female
external genitalia. Female patients have normal genitalia
but show a lack of pubertal development in adoles-
cence. An increased production of mineralocorticoids
often leads to hypertension and hypokalemia in both
sexes (17, 18). Therefore, P450c17 can be considered
as the qualitative regulator of steroidogenesis by deter-
mining which kind of steroids will be produced (19): min-
eralocorticoid where P450c17 is absent, glucocorticoids
when 17α-hydroxylation is active, and sex hormones
when 17,20-cleavage takes place. Thus, knowledge con-
cerning P450c17 will be of great impact for the under-
standing of hypertension, adrenarche, puberty, and hy-
perandrogenism, with obvious implications for fertility.
Two main issues are confirmed by molecular, clinical and
enzymatic studies of mutant P450c17: in 46, XY individu-
als with the complete deficiency impaired masculinization
is the constant clinical hallmark of this DSD (15, 20-27). In
46,XX individuals, in whom the diagnosis seems to be in-
frequently made (21, 27-30), it is mandatory to include
this rare disease in the differential diagnosis of delayed
puberty in girls since a missed diagnosis can lead to se-
vere hypertension and reproductive dysfunction (31).
Second, although P450c17 is the first hypertensive de-
fect of steroidogenesis to be identified (17), age of onset
and severity of hypertension do not seem to be as con-
sistent. Two obvious possibilities can be considered to
explain the differences in the patients’ hypertension. The
easiest explanation is dietary: the patients with normal
blood pressure may simply be on low-salt diets. The sec-
ond possibility is that the CYP17A1 some mutations are
more deleterious than others. This hypothesis is consis-
tent with model of the structure of P450c17 (32), although
prediction of the precise enzymatic consequences of a
mutation from any structure is not trivial. Careful exami-
nation and follow-ups of these patients might offer the
chance of identifying factors influencing P450c17 activi-
ties, with possible impact in their clinical management.
For instance, accurate long-term monitoring in 2 of our
patients (27) suggested to us that estrogen treatment in
P450c17-deficient patients might worsen the enzymatic
defect, as previously implied (33). Estrogens have been
previously shown to block androgen production in the
gonads by inhibiting, through the estrogen receptor, ex-
pression and activity of P450c17. Since adrenal cortex al-
so expresses ERα, it is possible that estrogens exert the
same effect in this organ. Based on an elegant study in
monkeys, Wood and collaborators suggested that (ex-
ogenous) estrogens [oral contraceptives (OC) and con-
jugated estrogens (CEE)] divert adrenal steroidogenesis
toward cortisol and away from androgen synthesis, ulti-
mately leading to androgen-deficient hypercortisolemic
state (34). This also seems to be true in humans, as dem-
onstrated by studies in women under OC (35-37) or un-
der post-menopause estrogen replacement therapy (38-
42). If cortisol cannot be synthesized, as in the case of
P450c17 deficiency, the putative estrogen-driven “de-
tour” would be further switched toward the only path-
Fig. 3 - Abdominal imaging in patient 6. A) magnetic resonance imaging (MRI) at presentation (ov= ovary): hypoplastic uterus, nor-
mal vagina, ovarian masses indicated by arrows (biggest mass 4 cm diameter). B) Ultrasonography (US) at presentation: uterus 3.5×1.4
cm, polycystic mass with a biggest cyst 5×3.7 cm with a thick wall (2-3 mm). The ovaries are not well delimited. C: US after 15 months
of estrogen therapy (16 μg estradiol), showing reduction of the ovarian masses and signs of uterine maturation: uterus 5 cm; right ovary
3.6×3.2×1.6; cm left ovary 5×3.6×1.5 cm; left mass 2.8 cm diameter.
A B C
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way that is still intact, i.e. the mineralocorticoid synthet-
ic route. 46,XX P450c17-deficient patients often present
with gonadal masses, most likely caused by acyclic hy-
perstimulation due to the elevated levels of gonadotropin
(27, 43, 44).
That poses a dilemma concerning the therapeutical man-
agement of 46, XX P450c17-deficient patients. In fact,
these patients need estrogens to induce development
of secondary sexual characteristics (as 46, XY patients do)
and to maintain bone density but also to suppress go-
nadotropin levels, responsible for ovarian hyperstimula-
tion and endometrial dysfunction. In some patients, how-
ever, estrogens might aggravate hypertension. As alter-
native, GnRH agonist in combination with lower doses of
estrogens might be used to suppress gonadotropin, in-
duce puberty and maintain female phenotype. The con-
trol of blood pressure can be initially achieved by salt re-
striction, although mineralocorticoid antagonists might
be necessary later in life.
Cytochrome b5 deficiency causes primarily methe-
moglobinemia type IV (45). One of the affected patients
exhibited female genitalia at birth and was subsequent-
ly determined to be a 46 XY, DSD (46), likely because of
defective P450c17 activity, which is dependent form
CYB5.
Male patients affected by CAH due to 3β-hydroxysteroid
dehydrogenase deficiency display incomplete pre-natal
masculinization due to the impaired synthesis of bioactive
androgens, and salt-loss due to lack of mineralocorticoid
(47, 48). XX subjects have normal female external geni-
talia or mild virilization due to the action of the weak an-
drogen DHEA.
21-hydroxylase deficiency accounts for most cases of
CAH (80-90%, depending on the ethnic group) (49, 50).
Clinical consequences of 21-hydroxylase deficiency arise
from overproduction of androgens.
The clinical presentation of patients with CAH is hetero-
geneous and depends on the type of gene mutation as
well as on the sex of the patient (51). Some newborns
with CAH may thus present without clinical signs or symp-
toms post-natally and in these the diagnosis of CAH can
obviously not be made on clinical basis. The unrecog-
nized and thus untreated disease may entail life-threat-
ening salt-wasting crisis in the newborn period and lead
to morbidity later in life, including precocious puberty
and short stature. Thus, the benefit of a neonatal screen-
ing that fulfils the criteria proposed for feasibility for neo-
natal screening and that can prevent delayed diagnosis
of CAH and its associated morbidity and mortality is ev-
ident (52, 53).
Steroid 21-hydroxylase (CYP21, also termed CYP21A2
and P450c21) is a cytochrome P-450 enzyme located in
the endoplasmic reticulum. It catalyzes the conversion of
17-hydroxyprogesterone to 11-deoxycortisol, a precur-
sor of cortisol, and the conversion of progesterone to de-
oxycorticosterone, a precursor of aldosterone (Fig. 2).
Patients with 21-hydroxylase deficiency cannot synthesize
cortisol efficiently, and as a result, the adrenal cortex is
stimulated by corticotropin and overproduces cortisol pre-
cursors. Some of these precursors are used for the biosyn-
thesis of sex hormones, which may cause signs of andro-
gen excess, including ambiguous genitalia in newborn
girls and rapid post-natal growth in both sexes. Con-
comitant aldosterone deficiency may lead to salt wasting
with consequent failure to thrive, hypovolemia, and shock.
Clinical presentation
Different phenotypes are observed. A severe form with a
concurrent defect in aldosterone biosynthesis (salt-wast-
ing type) and a form with apparently normal aldosterone
biosynthesis (simple virilizing type) are called classic 21-
hydroxylase deficiency. There is also a mild, non-classic
form that may be asymptomatic or associated with signs
of post-natal androgen excess (54).
Classic 21-hydroxylase deficiency is detected in approx-
imately 1 in 16,000 births in most populations (55). In
Switzerland, the disease is detected in approximately
1:10,000 with a carrier frequency of 1:50, that is in agree-
ment with figures of other European countries. The non-
classic form occurs in approximately 0.2% of the gener-
al white population but is more frequent (1 to 2%) in cer-
tain populations, such as Jews of Eastern European ori-
gin (56). The lower general frequency is similar to that
estimated on the basis of CYP21 genotyping of newborns
in New Zealand (0.3%) (57).
Salt wasting
Approximately 75% of patients with classic 21-hydroxy-
lase deficiency have severely impaired 21-hydroxylase
activity and therefore cannot adequately synthesize al-
dosterone. Elevated levels of 21-hydroxylase substrates
– mostly 17-hydroxyprogesterone – may act as miner-
alocorticoid antagonists, exacerbating the effects of al-
dosterone deficiency (58). Since aldosterone regulates
sodium homeostasis, renal sodium excretion in untreat-
ed patients is excessive and can result in hypovolemia
and hyperreninemia. Such patients cannot excrete potas-
sium efficiently and are prone to hyperkalemia, especially
in infancy. Cortisol deficiency in these patients contrib-
utes to poor cardiac function, poor vascular response to
catecholamines, a decreased glomerular filtration rate,
and increased secretion of ADH (59). Thus, cortisol and
aldosterone deficiency together cause hyponatremic de-
hydration and shock in inadequately treated patients.
Moreover, since the development of the adrenal medul-
la is in part dependent on glucocorticoids, patients with
salt-wasting 21-hydroxylase deficiency may also have cat-
echolamine deficiency, potentially aggravating shock (60).
Patients with the salt-wasting form are identified through
the measurement of serum electrolytes, aldosterone, and
plasma renin and the finding of expected abnormalities
hyperkalemia, low levels of aldosterone, and hyper-
reninemia.
Ambiguous genitalia
Girls with classic 21-hydroxylase deficiency are exposed
in utero to high levels of adrenal androgens from ap-
proximately the 7th week of gestation. Thus, such girls
have ambiguous external genitalia. The uterus, fallopian
tubes, and ovaries are normally formed, but there is no
development of the wolffian duct. In contrast, affected
boys have no overt signs of the disease except variable
and subtle hyperpigmentation of the scrotum and penile
enlargement.
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Post-natal virilization
In untreated or poorly treated patients, long-term ex-
posure to high levels of sex hormones promotes rapid
somatic growth and advanced skeletal age, which leads
to premature epiphyseal fusion and low adult height.
Pubic and axillary hair may develop early. Clitoral
growth may continue in girls. Young boys may have pe-
nile growth despite having small testes, since the an-
drogens are adrenal in origin. Long-term exposure to
androgens may activate the hypothalamic-pituitary-go-
nadal axis, causing central precocious puberty.
Reproductive function
In girls with any form of 21-hydroxylase deficiency, signs
of reproductive abnormalities, such as oligomenorrhea
or amenorrhea, may develop in adolescence (61, 62). The
issue of fertility is mainly related to psychosocial adjust-
ment. Women with classic salt-wasting or simple viriliz-
ing disease who were born and treated in the early days
tend to avoid heterosexual relationships, especially if the
surgical correction of the external genitalia was inade-
quate or androgen levels were constantly elevated (63).
As surgical, medical, and psychological treatments have
improved, more women with 21-hydroxylase deficiency
have successfully completed pregnancies and given birth,
most by cesarean section (64, 65). About 80% of women
with simple virilizing disease and approximately 60% of
those with the severe salt-wasting form are fertile.
As compared with affected women, affected men have
fewer problems with reproductive function, specifically
gonadal function. Most have normal sperm counts and
are able to father children (66, 67). One relatively com-
mon form of gonadal abnormality in affected males is
the development of testicular adrenal rests, detectable
by sonographic imaging before they become palpable
(68). Such tumors have been detected even in childhood
(69), suggesting that the search for these tumors should
begin no later than adolescence. In males with salt wast-
ing, testicular rest tissue may be accompanied by defi-
cient spermatogenesis despite treatment. Infertility can
be circumvented by intracytoplasmic sperm injection
(70). These tumors are always benign and orchidectomy
is usually not necessary. Proper medical treatment con-
sists of pituitary suppression with dexamethasone, since
the tumors are usually responsive to corticotropin.
Patients with simple virilizing 21-hydroxylase deficiency
Patients with simple virilizing 21-hydroxylase deficien-
cy do not synthesize cortisol efficiently, but aldosterone
secretion is sufficient to maintain sodium balance.
Whereas the disease is usually diagnosed in female pa-
tients shortly after birth due to genital ambiguity, the
diagnosis is often delayed for several years in male pa-
tients. Without newborn screening, affected boys are
usually identified when signs of androgen excess de-
velop. Later diagnosis is associated with greater diffi-
culty in achieving hormonal control, abnormal puberty,
and short stature.
Patients with non-classic disease
Patients with non-classic 21-hydroxylase deficiency pro-
duce normal amounts of cortisol and aldosterone at the
expense of mild-to-moderate overproduction of sex hor-
mone precursors. A few non-classic cases are detected
by newborn-screening programs, but most are missed
because of the relatively low base-line levels of 17-hy-
droxyprogesterone (71-73). Hirsutism is the single most
common symptom at presentation in approximately 60%
of symptomatic women, followed by oligomenorrhea
(54%) and acne (33%) (74). Thus, non-classic 21-hydrox-
ylase deficiency and polycystic ovarian syndrome may
present in similar ways.
Heterozygotes
Individuals who are heterozygous for CYP21A2 mutations
often have slightly higher 17-hydroxyprogesterone levels
after adrenal stimulation than unaffected subjects. Al-
though it has been suggested that heterozygotes might
be more likely to have signs of androgen excess than
would genetically unaffected subjects, case-control stud-
ies do not support this concept (75).
Diagnosis
Newborn screening
Classic 21-hydroxylase deficiency is characterized by
markedly elevated serum levels of 17-hydroxyproges-
terone, the main substrate for the enzyme. Basal serum
17-hydroxyprogesterone values measured by radioim-
munoassay after extraction usually exceed 300 nmol/l in
infants with classical CAH, whereas the levels in normal
newborns are below 3 nmol/l. This difference makes it
possible to screen newborns for the disorder with the use
of dried blood spots on filter paper. Screening minimizes
delays in diagnosis, especially in male patients, and re-
duces morbidity and mortality from adrenal crises.
In recent years molecular diagnosis has been applied to
confirm a diagnosis of CAH at the DNA level. The ad-
vantages of this method as second-tier testing rely on its
high specificity.
Other diagnostic procedures
The gold standard for differentiating 21-hydroxylase de-
ficiency from other steroidogenic enzyme defects is the
corticotropin (Synachten) stimulation test, performed by
injecting a 0.125-mg or 0.25-mg bolus of ACTH and mea-
suring baseline and stimulated levels of 17-hydroxypro-
gesterone. Blood samples are obtained at baseline and
60 min after the administration of ACTH. Except for pre-
mature infants, there are no age-related differences in
the criteria for the diagnosis of 21-hydroxylase deficien-
cy on the basis of 17-hydroxyprogesterone levels.
The severity of hormonal abnormalities depends on the
type of 21-hydroxylase deficiency. Patients with salt-wast-
ing disease have the highest 17-hydroxyprogesterone lev-
els (up to 3000 nmol/l after corticotropin stimulation), fol-
lowed by patients with simple virilizing disease, who usu-
ally have somewhat lower levels (300 to 1000 nmol/l). Pa-
tients with non-classic disease have smaller elevations (50
to 300 nmol/l), especially in the newborn period. Random
measurements of basal serum 17-hydroxyprogesterone
levels are often normal in patients with non-classic dis-
ease unless the values are obtained in the early morning.
Thus, the diagnosis is most reliably made by measuring
the patient’s response to corticotropin stimulation.
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Other hormones whose levels are usually elevated in pa-
tients with 21-hydroxylase deficiency include proges-
terone, androstenedione, and to a lesser extent, testos-
terone. An atypical steroid, 21-deoxycortisol, is also ele-
vated but is not routinely assayed. Mutation analysis can
confirm the diagnosis and is used in some newborn-
screening programs.
Genetics
Mutations in the CYP21 (CYP21A2) gene, which is located
in the highly polymorphic human leucocyte antigen his-
tocompatibility complex on chromosome 6p21.3 along
with a pseudogene, CYP21A1P (CYP21P), are responsi-
ble for causing 21-hydroxylase deficiency. Although
CYP21A2 and CYP21P have 98% nucleotide-sequence
identity, the latter has accumulated several mutations that
totally inactivate its gene product. Most mutations caus-
ing 21-hydroxylase deficiency arise from two types of re-
combination between CYP21A2 and CYP21P (54).
The search for mutations is made easier since the great
majority (up to 95%) of the mutant alleles will carry 1 of
the 10 pseudogene mutations. On the other hand, the
high degree of sequence identity between the active gene
and the pseudogene renders the specific amplification of
the CYP21A2 active gene rather challenging (76).
Treatment
CAH is a chronic disease that requires long-term therapy.
In the classical form of the disease glucocorticoids are
required not only to overcome the cortisol deficiency
mostly in stress situations, but also to suppress the ACTH-
driven stimulation of adrenal androgens. In classical CAH,
mineralocorticoids substitution is required and salt sup-
plementation is advisable in infancy. Surgical correction
of the ambiguous genitalia in girls is also part of the man-
agement of these patients. It is not recommended to
treat infant and children affected by the non-classical
form of the disease until symptoms and signs of andro-
gen excess become evident [for more details see (78)].
Steroid 11β-hydroxylase deficiency, which is responsible
for 10-20% of cases of CAH, produces symptoms of an-
drogen excess similar to those in 21-hydroxylase defi-
ciency. The blocked enzymatic step also results in accu-
mulation of 11-deoxycorticosterone which has mineralo-
corticoid activity, leading in untreated patients to hyper-
tension (48).
DEFECTS LEADING TO ABNORMALITIES
OF SALT-WATER BALANCE
The second group of diseases includes rare abnormali-
ties in the final step in the biosynthesis of aldosterone.
Corticosterone methyl oxidase deficiency
The CYP11B2 gene encodes a steroid 11/18-β-hydroxy-
lase, also called aldo-synthase, that functions in mito-
chondria in the zona glomerulosa of the adrenal cortex to
synthesize the mineralocorticoid aldosterone. The en-
zyme catalyzes all 3 necessary reactions: the 11-β-hy-
droxylation of 11-deoxycorticosterone (11-DOC) to cor-
ticosterone (B); the 18-hydroxylation of corticosterone to
18-hydroxycorticosterone (18-OHB); and the 18-oxida-
tion of 18-hydroxycorticosterone to aldosterone (78). De-
fects in this gene can cause two clinical entities with over-
lapping but not identical phenotypes and different bio-
chemical features. Corticosterone methyl oxidase (CMO)
type I deficiency is an autosomal recessive disorder
caused by a defect in the penultimate biochemical step
of aldosterone biosynthesis, the 18-hydroxylation of cor-
ticosterone (B) to 18-hydroxycorticosterone (18-OHB).
This enzymatic defect results in decreased aldosterone
and salt-wasting. In CMO I deficiency, aldosterone is un-
detectable, whereas its immediate precursor, 18-OHB,
is low or normal. These patients have an increased ratio
of corticosterone to 18-OHB (79), A defect in the final
step in aldosterone synthesis, the oxidation of 18-OHB
to aldosterone, results in CMO type II deficiency, in which
aldosterone can be low or normal, but at the expense of
increased secretion of 18-OHB. These patients have a
low ratio of corticosterone to 18-OHB (79).
Although aldo-synthase/corticosterone methyl oxidase
deficiency impairs the synthesis of aldosterone with con-
sequent salt-loss in the neonatal period, some patients
become completely asymptomatic later in life.
Glucocorticoid-suppressible hyperaldosteronism is an au-
tosomal dominant disease characterized by mineralo-
corticoid hypertension due to an abnormal stimulatory
action of ACTH on aldosterone synthesis. This is due to
unequal crossing over between the zona glomerulosa
11β-hydroxylase (angiotensin II regulated) and the zona
fasciculata 11β-hydroxylase (ACTH regulated) genes (78).
Defects in the inactivation of cortisol, such as 11β-hy-
droxysteroid dehydrogenase type II deficiency, can lead
to hypertension with hypokalemia in absence of ele-
vated levels of mineralocorticoids. The mechanism un-
derlying such phenomenon is the prolonged half-life of
cortisol that binds to the relatively unselective miner-
alocorticoid receptor in the kidney and acts like a min-
eralocorticoid, causing the so-called apparent miner-
alocorticoid excess syndrome (80). The defect of 11β-
hydroxysteroid dehydrogenase type I isoform is called
cortisone reductase deficiency (CRD). CRD is a disorder
in which there is a failure to regenerate the active glu-
cocorticoid cortisol (F) from cortisone (E) via the enzyme
11β-hydroxysteroid dehydrogenase (11β-HSD1) (81). A
lack of cortisol regeneration stimulates ACTH-mediat-
ed adrenal hyperandrogenism, with males manifesting
in early life with precocious pseudopuberty and females
presenting in midlife with hirsutism, oligomenorrhea,
and infertility (82-87). Biochemically, CRD has been di-
agnosed through the assessment of urinary cortisol and
cortisone metabolites and consists of measuring the
tetrahydrocortisol (THF) plus 5 -THF/tetrahydrocortisone
(THE) ratio (THF+5–THF/THE ratio); in CRD patients, the
ratio is typically <0.1 (reference range 0.7-1.2) (81).
11β-HSD1 (encoded by the HSD11B1 gene) is a bidirec-
tional enzyme in vitro acting as a reductase (cortisone to
cortisol) or as a dehydrogenase (cortisol to cortisone) but
in vivo functions primarily as a reductase (81). It therefore
appeared that HSD11B1 was the obvious candidate gene
mutated in CRD; however, no coding mutations directly
affecting enzyme activity had been identified (82, 84, 86).
The cortisol-regenerating reductase activity of 11β-HSD1
is critically dependent upon the provision of reduced
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NADPH in the endoplasmic reticulum lumen and is pro-
vided by the enzyme hexose-6-phosphate dehydroge-
nase (H6PDH, encoded by the H6PD gene). CRD has
been shown to demonstrate a triallelic digenic pattern of
inheritance involving mutations in the HSD11B1 and
H6PD genes (83). More recently, Lavery et al. could de-
monstrate that CRD is caused by inactivating mutations
in the H6PD gene, rendering the 11β-HSD1 enzyme un-
able to operate as an oxoreductase, preventing local glu-
cocorticoid regeneration (88). These data highlight the
importance of the redox control of cortisol metabolism
and the 11β-HSD1-H6PDH pathway in regulating hy-
pothalamic-pituitary-adrenal axis activity.
DEFECTS LEADING TO ABNORMALITIES
OF SEXUAL DEVELOPMENT
The third group of defects is characterized by deficien-
cies of enzymes responsible for the final steps of sex hor-
mone synthesis, such as 17,20-lyase, 17β-hydroxysteroid
dehydrogenase (17β-HSD), 5α-reductase and aromatase.
Deficient activity of 17,20-lyase, 17β-HSD, and 5α-re-
ductase enzymes leads to 46,XY DSD with varying gen-
ital ambiguity in XY individuals. In XX individual the gen-
italia are generally normal. In 17,20-lyase (or 17,20-
desmolase) deficiency, there is no male or female pu-
bertal development. Cortisol is normal, and there is no
hypertension. The deficient enzyme is the same as in
17α-hydroxylase deficiency and it is unknown why the
defect manifests itself as 17α-hydroxylase in some, and
as 17,20-lyase deficiency in other families. Possibly, es-
trogen replacement induces a conversion to 17α-hy-
droxylase deficiency (89). In 17β-HSD deficiency, there
is some male pubertal development in XY individuals
due to androstenedione, and often gynecomastia due
to estrone. In XX individuals, there is mild virilization and
insufficient development of estrogenic sexual character-
istics. In 5α-reductase deficiency, male puberty is pre-
sent in XY subjects because testosterone is sufficient,
and dihydrotestosterone (DHT) is not necessary for ex-
pression of male sexual secondary characteristics. In XX
individuals there are no symptoms. Interestingly, at the
time of expected puberty the patients affected by these
deficiencies, display some degree of virilization. Particu-
larly high is the incidence of 5α-reductase deficiency in
the Dominican Republic (90). Patients of both sexes af-
fected by aromatase deficiency due to loss-of-function
mutation in the CYP19 gene show a delayed somatic de-
velopment and slower skeletal maturation, with conse-
quent tall adult stature. Female patients affected by aro-
matase deficiency display various degrees of genital am-
biguity, due to the lack of pre-natal exposure to estro-
gens, and signs of hyperandrogenism, such as acne (91).
Morishima et al. (92) described a 28-yr-old XX proband
and her 24-yr-old XY sib. The mother of the proband ex-
hibited signs of progressive virilization during both preg-
nancies that regressed post partum. The XX proband,
followed since infancy, exhibited the cardinal features of
the aromatase deficiency syndrome. She had non-adre-
nal female pseudohermaphroditism at birth and under-
went repair of the external genitalia, including a clitorec-
tomy. At puberty, she developed progressive signs of
virilization, pubertal failure with no signs of estrogen ac-
tion, hypergonadotropic hypogonadism, polycystic
ovaries on pelvic sonography, and tall stature. The basal
concentrations of plasma testosterone, androstenedione,
and 17-hydroxyprogesterone were elevated, whereas
plasma estradiol was low. Hormone replacement thera-
py led to breast development, menses, resolution of
ovarian cysts, and suppression of the elevated FSH and
LH values. Her adult height was 177.6 cm. Her brother
was 204 cm tall with eunuchoid skeletal proportions. He
was sexually fully mature and had macroorchidism. The
bone age was 14 yr at a chronologic age of 24 yr. Strik-
ing osteopenia was noted at the wrist and at other sites.
The observations in these sibs were considered consis-
tent with the following interpretations by the authors: a)
estrogens are essential for normal skeletal maturation
and proportions (but not linear growth) in men as well
as in women, the accretion and maintenance of bone
mineral density and mass, and the control of the rate of
bone turnover; b) estrogens have a significant role in the
sex steroid-gonadotropin feedback mechanism in the
male, even in the face of high circulating testosterone; c)
deficient estrogens in the adult male are associated with
hyperinsulinemia and abnormal plasma lipids; d) pla-
cental aromatase has a critical role in protecting the fe-
male fetus from fetal masculinization and the pregnant
woman from virilization. All the described case confirm
these observations, although the phenotype might be
variable (93-96).
By standards of other CYP genes, CYP19 is extraordinar-
ily large (more than 50 kb). The large size of the gene is
probably related to the transcription of CYP19 in differ-
ent cell types under the regulation of different promoters,
which give rise to transcripts with unique 5-prime non-
coding termini. The distal promoter (I.1) is responsible
for expression uniquely in the placenta, while the proxi-
mal promoter (II), which regulates expression via a cAMP-
dependent signaling pathway, is responsible for expres-
sion in the gonads. Transcripts in breast adipose tissue
contain 5-prime termini corresponding to expression de-
rived from use of promoters I.4 predominantly as well as
II and I.3 [reviewed by Simpson in (97-99)].
Gain-of-function rearrangements in chromosome 15q21.2-
q21.3 leading to fusion of the CYP19 gene with CGNL1,
TMOD3 (100) or TRPM7 (101) promoter resulting in se-
vere estrogen excess owing to the overexpression of aro-
matase in many tissues cause aromatase excess syn-
drome. Aromatase excess syndrome is an autosomal
dominant disorder characterized by increased extraglan-
dular aromatization of steroids that presents with het-
erosexual precocity in males and isosexual precocity in
females (102-104).
An intriguing case is that of P450 Oxidoreductase (POR)
deficiency. Cytochrome P450 oxidoreductase is a flavo-
protein that donates electrons to all microsomal P450 en-
zymes, including the steroidogenic enzymes P450c17,
P450c21, and CYP51A1 (105). In 1985, a clinical report
described a patient with genital ambiguity and an ab-
normal urinary steroid profile suggesting partial com-
bined deficiencies of what was then thought to be 3
distinct steroidogenic enzymes: 17α-hydroxylase, 17,20
lyase, and 21-hydroxylase (106). Affected girls are born
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with ambiguous genitalia, indicating intrauterine an-
drogen excess. After birth, however, virilization does
not progress and amounts of circulating androgens are
low or normal. Conversely, affected boys are sometimes
born undermasculinized. The majority but not all of pa-
tients described to date with POR deficiency also had a
pattern of skeletal malformations termed Antley-Bixler
syndrome. This disorder is characterized by craniosyn-
ostosis (premature fusion of bones of the skull), radio-
ulnar or radio-humeral synostosis, bowed femora and
other more variable skeletal disorders (107, 108). Find-
ings of biochemical investigations of urinary steroid ex-
cretion in affected patients have shown accumulation
of steroid metabolites, indicating impaired C17 and
C21 hydroxylation, suggesting concurrent partial defi-
ciencies of the 2 steroidogenic enzymes, P450C17 and
P450C21. However, sequencing of the genes encod-
ing these enzymes showed no mutations, which ac-
corded with the idea of a defect in a cofactor that in-
teracts with both enzymes. As these steroidogenic en-
zyme activities were known to be catalyzed by Type II
cytochrome P450 enzymes, it was suggested that this
patient had a disorder in the electron donor for these
enzymes, P450 oxidoreductase (105). This fascinating
idea remained dormant until Fluck first reported 4 cas-
es of POR deficiency (109). Since that time, about 50
additional patients have been reported [for review see
(110, 111)].
APPENDIX
*Cytochrome P450 (abbreviated CYP, P450, infrequently CYP450) is a
very large and diverse superfamily of hemoproteins found in all domains
of life (1, 2). Cytochromes P450 use a plethora of both exogenous and en-
dogenous compounds as substrates in enzymatic reactions. Usually they
form part of multicomponent electron transfer chains, called P450-con-
taining systems.
The most common reaction catalyzed by cytochrome P450 is a monooxy-
genase reaction, e.g. insertion of one atom of oxygen into an organic
substrate (RH) while the other oxygen atom is reduced to water:
RH + O2 + 2H+ + 2e– → ROH + H2O
CYP enzymes have been identified from all lineages of life, including
mammals, birds, fish, insects, worms, sea squirts, sea urchins, plants, fun-
gi, slime molds, bacteria and archaea. More than 8100 distinct CYP se-
quences are known (as of February 2009; see the website of the P450
Nomenclature Committee for current counts, http: //drnelson.utmem.edu
/CytochromeP450.html).
The name cytochrome P450 is derived from the fact that these are colored
(‘chrome’) cellular (‘cyto’) proteins, with a “pigment at 450 nm”, so named
for the characteristic Soret peak formed by absorbance of light at wave-
lengths near 450 nm when the heme iron is reduced and complexed to
carbon monoxide.
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